327 related articles for article (PubMed ID: 28746872)
1. Aberrant Proteostasis of BMAL1 Underlies Circadian Abnormalities in a Paradigmatic mTOR-opathy.
Lipton JO; Boyle LM; Yuan ED; Hochstrasser KJ; Chifamba FF; Nathan A; Tsai PT; Davis F; Sahin M
Cell Rep; 2017 Jul; 20(4):868-880. PubMed ID: 28746872
[TBL] [Abstract][Full Text] [Related]
2. Haploinsufficiency of a Circadian Clock Gene
Singla R; Mishra A; Lin H; Lorsung E; Le N; Tin S; Jin VX; Cao R
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35682995
[TBL] [Abstract][Full Text] [Related]
3. REV-ERBα alters circadian rhythms by modulating mTOR signaling.
Dadon-Freiberg M; Chapnik N; Froy O
Mol Cell Endocrinol; 2021 Feb; 521():111108. PubMed ID: 33285244
[TBL] [Abstract][Full Text] [Related]
4. PI3K-PTEN dysregulation leads to mTOR-driven upregulation of the core clock gene BMAL1 in normal and malignant epithelial cells.
Matsumoto CS; Almeida LO; Guimarães DM; Martins MD; Papagerakis P; Papagerakis S; Leopoldino AM; Castilho RM; Squarize CH
Oncotarget; 2016 Jul; 7(27):42393-42407. PubMed ID: 27285754
[TBL] [Abstract][Full Text] [Related]
5. Hypothalamic orexin and mechanistic target of rapamycin activation mediate sleep dysfunction in a mouse model of tuberous sclerosis complex.
Zhang B; Guo D; Han L; Rensing N; Satoh A; Wong M
Neurobiol Dis; 2020 Feb; 134():104615. PubMed ID: 31605778
[TBL] [Abstract][Full Text] [Related]
6. Moving to the Rhythm with Clock (Circadian) Genes, Autophagy, mTOR, and SIRT1 in Degenerative Disease and Cancer.
Maiese K
Curr Neurovasc Res; 2017; 14(3):299-304. PubMed ID: 28721811
[TBL] [Abstract][Full Text] [Related]
7. Tuberous sclerosis complex.
Hasbani DM; Crino PB
Handb Clin Neurol; 2018; 148():813-822. PubMed ID: 29478616
[TBL] [Abstract][Full Text] [Related]
8. mTOR signaling regulates central and peripheral circadian clock function.
Ramanathan C; Kathale ND; Liu D; Lee C; Freeman DA; Hogenesch JB; Cao R; Liu AC
PLoS Genet; 2018 May; 14(5):e1007369. PubMed ID: 29750810
[TBL] [Abstract][Full Text] [Related]
9. Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice.
Tsai PT; Hull C; Chu Y; Greene-Colozzi E; Sadowski AR; Leech JM; Steinberg J; Crawley JN; Regehr WG; Sahin M
Nature; 2012 Aug; 488(7413):647-51. PubMed ID: 22763451
[TBL] [Abstract][Full Text] [Related]
10. Complex Neurological Phenotype in Mutant Mice Lacking Tsc2 in Excitatory Neurons of the Developing Forebrain(123).
Crowell B; Lee GH; Nikolaeva I; Dal Pozzo V; D'Arcangelo G
eNeuro; 2015; 2(6):. PubMed ID: 26693177
[TBL] [Abstract][Full Text] [Related]
11. Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation.
Hwang SK; Lee JH; Yang JE; Lim CS; Lee JA; Lee YS; Lee K; Kaang BK
Mol Brain; 2016 May; 9(1):56. PubMed ID: 27216612
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
Mi R; Ma J; Zhang D; Li L; Zhang H
J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
[TBL] [Abstract][Full Text] [Related]
13. A Novel Bmal1 Mutant Mouse Reveals Essential Roles of the C-Terminal Domain on Circadian Rhythms.
Park N; Kim HD; Cheon S; Row H; Lee J; Han DH; Cho S; Kim K
PLoS One; 2015; 10(9):e0138661. PubMed ID: 26394143
[TBL] [Abstract][Full Text] [Related]
14. Deficient TSC1/TSC2-complex suppression of SOX9-osteopontin-AKT signalling cascade constrains tumour growth in tuberous sclerosis complex.
Jin F; Jiang K; Ji S; Wang L; Ni Z; Huang F; Li C; Chen R; Zhang H; Hu Z; Zha X
Hum Mol Genet; 2017 Jan; 26(2):407-419. PubMed ID: 28013293
[TBL] [Abstract][Full Text] [Related]
15. The Stress-Induced Atf3-Gelsolin Cascade Underlies Dendritic Spine Deficits in Neuronal Models of Tuberous Sclerosis Complex.
Nie D; Chen Z; Ebrahimi-Fakhari D; Di Nardo A; Julich K; Robson VK; Cheng YC; Woolf CJ; Heiman M; Sahin M
J Neurosci; 2015 Jul; 35(30):10762-72. PubMed ID: 26224859
[TBL] [Abstract][Full Text] [Related]
16. Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complex.
Hoogeveen-Westerveld M; Ekong R; Povey S; Mayer K; Lannoy N; Elmslie F; Bebin M; Dies K; Thompson C; Sparagana SP; Davies P; van Eeghen AM; Thiele EA; van den Ouweland A; Halley D; Nellist M
Hum Mutat; 2013 Jan; 34(1):167-75. PubMed ID: 22903760
[TBL] [Abstract][Full Text] [Related]
17. Brain Symptoms of Tuberous Sclerosis Complex: Pathogenesis and Treatment.
Mizuguchi M; Ohsawa M; Kashii H; Sato A
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206526
[TBL] [Abstract][Full Text] [Related]
18. PAK2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for Tuberous Sclerosis Complex.
Alves MM; Fuhler GM; Queiroz KC; Scholma J; Goorden S; Anink J; Spek CA; Hoogeveen-Westerveld M; Bruno MJ; Nellist M; Elgersma Y; Aronica E; Peppelenbosch MP
Sci Rep; 2015 Sep; 5():14534. PubMed ID: 26412398
[TBL] [Abstract][Full Text] [Related]
19. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
20. BMAL1-dependent regulation of the mTOR signaling pathway delays aging.
Khapre RV; Kondratova AA; Patel S; Dubrovsky Y; Wrobel M; Antoch MP; Kondratov RV
Aging (Albany NY); 2014 Jan; 6(1):48-57. PubMed ID: 24481314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
